SNP technologies for drug discovery: a current review by Voisey, Joanne & Morris, Phillip
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QUT Digital Repository:  
http://eprints.qut.edu.au/ 
Voisey, Joanne and Morris, Charles Phillip (2008) SNP technologies for drug 
discovery : a current review. Current Drug Discovery Technologies, 5(3). pp. 
230-235. 
 
          © Copyright 2008 Bentham Science Publishers Ltd 
SNP Technologies for Drug Discovery:  A Current Review 
 
Joanne Voisey* and Charles Phillip Morris 
 
Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Brisbane, Australia 
 
 
 
 
Please address all correspondence to 
 
Dr Joanne Voisey 
IHBI, QUT 
60 Musk Ave 
Kelvin Grove 4059 
Australia 
Ph: 61 7 31386261 
Fax:  1 7 31386030 
Email: j.voisey@qut.edu.au 
Abstract 
 
Single nucleotide polymorphisms (SNPs) are unique genetic differences between 
individuals that contribute in significant ways to the determination of human variation 
including physical characteristics like height and appearance as well as less obvious 
traits such as personality, behaviour and disease susceptibility.  SNPs can also 
significantly influence responses to pharmacotherapy and whether drugs will produce 
adverse reactions.  The development of new drugs can be made far cheaper and more 
rapid by selecting participants in drug trials based on their genetically determined 
response to drugs.  Technology that can rapidly and inexpensively genotype 
thousands of samples for thousands of SNPs at a time are therefore in high demand.  
With the completion of the human genome project, about 12 million true SNPs have 
been identified to date.  However, most have not yet been associated with disease 
susceptibility or drug response.  Testing for the appropriate drug response SNPs in a 
patient requiring treatment would enable individualised therapy with the right drug 
and dose administered correctly the first time.  Many pharmaceutical companies are 
also interested in identifying SNPs associated with polygenic traits so novel 
therapeutic targets can be discovered.  This review focuses on technologies that can 
be used for genotyping known SNPs as well as for the discovery of novel SNPs 
associated with drug response. 
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Introduction 
Every year in the United States there are millions of severe adverse drug reactions 
(ADR) resulting in over 100,000 deaths [1].  In addition, finding drugs that are 
effective can be a frustratingly slow and dangerous process as some people do not 
respond well to drugs that may be very effective in others.  For some disorders, such 
as certain psychiatric diseases, this has resulted in the phenomenon of polypharmacy 
where more drugs are prescribed than clinically warranted, resulting in increased 
ADRs and costs.  At the moment there is no simple way to determine how well or 
badly individual patients will respond to medication.  This often limits pharmaceutical 
companies to the development of drugs that are effective in the majority of patients, 
thereby disenfranchising the minority who do not respond well and missing out on 
potentially lucrative commercial opportunities.  For example a drug may have adverse 
responses in a significant proportion of the population so it would not normally be 
approved unless it was possible to define and exclude those with adverse reactions by 
genetic or other testing.  The ability to tailor drug therapy to the needs of an 
individual patient has therefore long been the goal of medical practitioners and the 
pharmaceutical industry.  We are now entering an era where pharmacogenomics 
offers the prospect of providing rapid, effective treatment for a multitude of disorders 
ranging from hypertension to schizophrenia.  The idea of pharmacogenomics is that 
the prescription of drugs can be customised to match each person’s genetically 
determined response to drugs and other therapies.  The way a person responds to 
drugs is largely determined by background genetic variants in many different genes.  
These genetic variants are usually single nucleotide polymorphisms (SNPs) that are 
scattered throughout the human genome and are responsible for most of the genetic 
variation seen in humans.  Therefore, an understanding of genetic make-up could 
result in improved drug efficacy by establishment of early therapeutic control with the 
minimum number and dose of drugs and consequent reduction in the side-effects of 
polypharmacy that is often seen in psychological disorders.  Testing to determine an 
individual’s genetic make-up would enable tailored medication so the right drug can 
be given at the correct dosage. 
 
Pharmacogenomics also has the potential to benefit drug development and testing 
because pharmaceutical companies could exclude subjects from clinical trials whose 
genetic makeup would result in an ADR or an ineffective response to a drug under 
evaluation.  Drug companies will therefore be able to increase the chance that a drug 
will produce good results in a particular group of patients, thereby increasing the 
chance that the drug under development will make it into the marketplace.  
Pharmacogenomic screening of selected SNPs in clinical trial subjects should also 
allow the clinical trials to be smaller, faster and less expensive.  SNPs discovered 
through pharmacogenomics studies can also be useful in discovering novel genes that 
influence disease development, thereby identifying potential targets for development 
of new drugs.   
 
Detection of SNPs and an understanding of their role in disease will be important as 
many complex diseases have a strong genetic component.  If the genetic component 
of the disease susceptibility can be identified then more effective and targeted 
treatments may be developed or the onset of disease may be prevented or severity 
reduced by determining and avoiding certain risk factors.  For example, dopamine is 
one pathway thought to play a role in schizophrenia development. Effective anti-
psychotic drugs are based on blocking dopamine receptors in the brain and single 
nucleotide polymorphism (SNPs) have been found in the dopamine receptors that 
alter gene function.  Also SNPs in genes that are associated with schizophrenia could 
be used to determine an individual’s risk of developing schizophrenia.  In the future 
we might be able to use schizophrenia risk assessment to aid in therapy and careful 
monitoring of environmental factors, preventing the onset of symptoms.  
 
Determining an individual’s genetic make-up by genetic testing of large numbers of 
SNPs or testing of SNPs in large numbers of individuals is therefore of fundamental 
importance in modern drug delivery and development.  To this end there have been 
innumerable techniques developed for SNP detection, many of which have been 
touted as “the solution” to SNP genotyping but there are few hat have survived to 
dominate the testing market.  This review focuses on genotyping methods for high-
throughput SNP detection in both the diagnostic setting and in the area of 
pharmaceutical drug trials and gene and drug discovery research.   
 
Technologies for Diagnostics 
In this section, examples will be presented of SNP genotyping technologies for the 
analysis of SNPs with diagnostic value that have previously been recognised to 
influence disease development or drug response.  Currently, these methods are usually 
employed in a diagnostic laboratory to determine whether a patient has a particular 
SNP or SNPs.  Almost all the techniques listed below also require an initial PCR 
amplification step which increases the number of target molecules and provides 
specificity to the reaction.   
 
Restriction Fragment Length Polymorphism (RFLP) Analysis  
This is the first and possibly still the most widespread DNA-based SNP detection 
technology, particularly in research laboratories where it was first developed for the 
diagnosis of simple genetic disorders such as sickle cell anaemia [2].  The method is 
only possible when the presence of a SNP creates or removes the recognition site of a 
restriction enzyme.  A PCR is performed that amplifies the region containing the SNP 
then the product is digested with the appropriate restriction enzyme and visualised by 
gel electrophoresis [3].  The main advantages are it is a very simple, flexile and cheap 
method for genotyping.  The main disadvantage of the technique is that not all SNPs 
will alter a restriction site, although this can sometimes be overcome by introducing a 
restriction site by PCR mutagenesis using non-matching primers [4]. 
 
Ligation 
Using specificity of ligase enzymes, allele discrimination can be achieved in ligase-
based assays.  When two oligonucleotides are annealed to template DNA and they are 
the perfect complement to the DNA sample, the two oligonucleotides are ligated 
together by ligase enzymes.  Allele-specific oligonucleotides are used to reveal base 
identity with the allele present in the target DNA when ligation has occurred.  The 
advantage of this method is that pre-amplification is not required if the method is 
combined with ligation chain reaction [5] or rolling circle amplification [6, 7].  The 
main disadvantage is that the reaction can be slow.   
 
Allele Specific Oligonucleotide (ASO) Hybridisation  
Allele specific oligonucleotide hybridisation is one of the first developed and most 
widely used SNP detection technologies.  It is also the basic technology used in many 
other high throughput assays, including most genotyping Gene Chips.  Short probes 
are constructed from sequence spanning the variant site that match either the normal 
or mutant sequence.  The challenge lies in designing probes that can discriminate 
between a single base mismatch and a perfectly matched hybrid [8].  Using stringent 
hybridisation conditions the probe will only bind to a perfectly matched sequence.  An 
array platform can be utilised to genotype many mutations at once.  Each probe on the 
array performs an ASO test for a specific sequence in the test DNA.  The 
disadvantages of ASO analysis are that the assay is often difficult to design and it is 
not always capable of detecting all SNPs, particularly when they involve repetitive 
sequences.  It is also a relatively costly and laborious assay.  Once the assay is 
designed, the method is fast and user friendly.   
 
Allele Specific Amplification (ASA) or ARMS (Amplification Refractory 
Mutation System)  
Like ASO, allele specific amplification (ASA) is one of the first developed and most 
widely used SNP detection technologies.  It is also the basic generic technology that 
underlies many other ‘testing platforms’.  In its simplest embodiment it involves 
conducting 2 PCR reactions on a DNA sample and running the products on a gel to 
see which allele(s) are present. This method is based on a simple amplification of 
either the wild-type or mutant sequence [9].  Three primers are used with one 
common to both alleles and the other two allele specific primers designed to pair with 
the common primer with each matching alternative alleles of the SNP.  Gel analysis 
can then determine the genotype by the presence or absence of a PCR product.  Two 
reactions must be set-up in parallel because the products are of the same size.  
Multiplexing can be achieved by designing the common primer to give different size 
products.  Multiplexing would be suited for genotyping a large number of samples for 
a panel of SNPs.  The main disadvantage is that specificity is often difficult to achieve 
and therefore false positives can be a problem.  The main advantage is that it is a 
simple and cheap method for genotyping.   
 
Another alternative to gel analysis is kinetic real-time ASA detection where the 
quantitative analysis allows more accurate determination of the genotype as it is 
possible to observe the kinetics of PCR product production for each allele, thereby 
eliminating some of the problems caused by non-specific amplification.   
 
While ASA is a component technology of many high throughput genotyping 
technologies its use as a simple gel-based ASA test is likely to remain localised to 
many small testing and research laboratories undertaking low throughput genotyping 
analysis. 
 
Single Nucleotide Extension (SNE) 
The generic technology involves the use of a primer annealed immediately abutting 
but not overlapping the SNP in question.  The primer is then extended with a DNA 
polymerase in the presence of appropriate mixes of dNTPs and labelled ddNTPs.  If 
the polymorphic site is complementary to the ddNTP then the base will be 
incorporated and the reaction will terminate and result in the incorporation of label 
into the extended DNA.  There are numerous embodiments of this generic technology.  
One of the earliest involved the use of a biotin-tagged extension primer that could be 
pulled out on a streptavidin coated microplate [10-12].  In this embodiment the 
ddNTP was labelled with fluorescein which could either be detected directly using a 
fluorescence plate reader or colorimetrically by using an alkaline phosphatase-
labelled anti-fluorescein antibody.  This is a simple, robust and cost-effective assay 
for genotyping single or multiple SNPs in a panel.  There are several SNP bioarray 
assays that have been marketed, including CodeLink™ a 4 chamber microarray for 
detecting 110 SNPs marketed by Amersham.  Orchid Biosciences has also produced a 
miniarray capable of very high sample or SNP throughput that detects a limited 
number of SNPs per miniarray in the base of a 384 well plate.  Both products involve 
multiplex amplification of the requisite regions of genes of interest followed by SNE 
with fluorescent ddNTPs.  The advantages are thousands of SNPs from thousands of 
samples can be analysed quickly and relatively cheaply.  The disadvantage is that 
PCR product must be generated before the assay is performed.  SNE is now a very 
well established SNP detection technology capable of detecting large numbers of 
SNPs or testing large numbers of samples.  It is likely that it will remain in use for the 
foreseeable future. 
 
Solid Phase Amplification (SPA) 
In the Solid Phase Amplification (SPA) assay a DNA sample is added to a microplate 
well containing PCR reagents and an allele specific amplification is performed.  One 
primer is bound to the well (solid phase primer) and one primer containing a 
fluorescent tag is added in solution which allows amplification and detection to be 
performed in the one reaction.  SPA can be performed in a microplate well or on a 
DNA chip based format [14].  The major advantage of SPA is that amplification and 
detection can be performed in the same well or DNA chip.  The main disadvantage is 
that allele specificity is often not achieved and the success of the method relies 
heavily on primer design.  Potentially, SPA can be applied to a range of high 
throughput testing platforms but to date its use has been limited. 
 TaqMan 
This method is based on real-time PCR.  It involves a probe being labelled with a 
reporter fluorescent dye and a quencher molecule [15].  The probe is designed to bind 
complementary to the target sequence and not to the target with a mismatched 
polymorphic base.  A forward and reverse primer is also designed to amplify the 
internal region containing the SNP.  The Taq DNA polymerase carries out extension 
of the primer and replicates the template.  The 5´ exonuclease activity of the 
polymerase also cleaves the probe, releasing the reporter molecule from the quencher.  
The fluorescent intensity of the reporter dye as a result increases but only when 
amplification occurs and only when the sequence matching the allele-specific 
TaqMan probe is present.  The advantage of this method is it is quantitative and is a 
closed tube assay preventing contamination.  The main disadvantage is that the 
TaqMan probes are costly and an expensive real-time PCR machine is required.  The 
assay is quite complex but it is now well accepted in large diagnostic laboratories and 
costs have been reduced by the introduction of low reaction volume microfluidics 
cartridges containing dried reagents necessary for the detection of predetermined 
SNPs.  The cartridges are capable of detecting either 48 different SNPs in 8 different 
samples or 384 different SNPs in one DNA sample.  However, the disadvantage is 
that the whole cartridge needs to be redesigned even if a change to or addition of a 
single SNP is required. 
 
Mass Spectrometry with Primer Extension 
Mass spectrometry (MS) SNP detection is a variation on SNE in that it involves 
extension of primers and allele specific termination by ddNTPs however, in MS SNP 
detection extension can involve more than one nucleotide and detection is on the basis 
of the mass of the extended primer.  Mass spectrometry measures the molecular 
weight of the product and doesn’t require a label for detection.  Combined with 
primer extension, MS is a powerful method for high throughput genotyping [16, 17].  
Primers are annealed to the target sequence adjacent to the SNP.  DNA polymerase, 
nucleotides and terminators allow extension of the primer through the polymorphic 
site.  The resulting mass of the primer extension product is analysed and used to 
determine the sequence of the nucleotide at the SNP site.  By multiplexing SNP 
reactions, hundreds of SNPs can be genotyped for thousands of samples relatively 
quickly and cheaply [17].  Most multiplexed primer extension MS detection assays 
are performed on a matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometer (MALDI-TOF MS).  Multiplexing can be performed by designing 
primers of various lengths which can therefore be distinguished by their different 
masses.  A universal termination mix, primers and polymerase is added and when a 
ddNTP is incorporated and terminated a different size product is produced and 
detected by mass.  This method is one of the most competitively priced methods for 
large scale genotyping.  Hundreds of samples for hundreds of SNPs can be analysed 
relatively quickly.  The main disadvantage is that a mass spectrometer with robotics 
and sophisticated analysis software is required.  Also, only one sample can be 
processed at a time and the sample must be of high purity for MS detection.  Despite 
these limitations, MS detection is now widely accepted and used for high throughput 
genotyping applications and it is likely to continue its popularity for many years to 
come, especially in research applications where flexibility in SNP assay design is of 
paramount importance. 
 
SNP Chips 
The principle behind hybridisation SNP Chips is that they basically work like a very 
large array of microscopic ASO hybridisation spots.  They are composed of an array 
of short oligonucleotides that detect the presence of various polymorphic alleles via 
allele specific hybridisation followed by fluorometric detection of bound DNA.  SNP 
Chips such as those manufactured by Affymetrix and Nanogen can be used for the 
detection of a panel of SNPs in one sample.  Advantages of DNA chips for 
diagnostics are that they have the ability to detect large numbers of SNPs in a single 
sample and they are automatable.  The disadvantages are that DNA chips are 
inflexible, i.e. they need to be redesigned to change even one SNP, and they are 
expensive if relatively few SNPs are tested on one sample.   
 
Point of Care Diagnostics 
Virtually all of the diagnostic methodologies described in the previous sections are 
relatively complex and require specialised equipment and expertise to be effectively 
implemented.  It is for this reason that they are exclusively restricted to specialist 
pathology laboratories or other specialist service providers.  However, for 
pharmacogenomics to be effectively implemented it will be necessary for genetic tests 
to be developed that can be conducted at or near the point of care (POC) for patients, 
e.g. at the patient’s bedside or more commonly, in a doctor’s clinic.  It will be far 
better for patients if they can leave a doctor’s clinic with a prescription for their 
correct drug rather than having to return some days later after the pathology testing 
results have been returned.  It is for this reason that it will be necessary to develop 
testing formats that can be used and interpreted by non-expert staff in small 
laboratories attached to doctor’s clinics or in the clinic itself.  While many POC tests 
have been developed for applications such as pregnancy, pathogen and glucose testing 
as well as bedside patient monitoring, very little progress has been made in the 
development of POC genetic testing.  One example of an early POC genetic testing 
format is given below. 
 
XTRANA POC Device 
This was one of the first integrated devices for POC diagnostics.  The XTRANA 
device is a closed self-contained device to perform all genotyping steps [18].  The 
sample is introduced into one end and a series of manipulations moves the sample to 
other compartments where extraction, amplification and detection occur.  Firstly, 
nucleic acid (for example a blood sample) is immobilised and purified on a solid 
binding matrix.  The target is then isothermally amplified directly on the solid phase.  
Detection is based on lateral-flow principles using dyed microsphere labels.  The 
advantage of the closed system is that contamination is prevented and all steps are 
performed in the one instrument, allowing for POC testing in molecular diagnostics.  
The disadvantage is that a great deal of development in basic technology is required 
and the current device is still rather cumbersome and poorly developed.  However 
once the instrument is purchased diagnostic testing is rapid and inexpensive.   While 
the device s somewhat crude it is notable as it is one of the first attempts to integrate 
the genotyping process into a simple device that could be used in a doctor’s clinic.  
 
Technologies for Gene Identification for Drug Discovery 
Complex traits are often complicated to unravel as they result from both genetic and 
environmental factors.  Only when a significant heritability for the trait can be 
demonstrated is it feasible to commence studies for locus identification.  Once a 
strong genetic susceptibility for a trait has been established a stringent study design 
must be implemented consisting of a large sample set and methodology that can yield 
sufficient statistical power to detect disease genes.   
 
The candidate gene approach and genome-wide scans are two complementary 
approaches for identifying complex trait loci.  With the first approach, candidate 
genes must be first identified by using information on what is known about the 
biology of the trait.  For example, in the past, candidate genes for schizophrenia have 
been based on key neurotransmitter pathways, such as dopamine and serotonin, and 
genes that affect neurotransmitter metabolism.  The genome scan uses thousands of 
SNPs that are evenly distributed across the genome to identify one or more loci that 
are in linkage with the trait.  Candidate gene and genome scan strategies can both be 
evaluated by either association or linkage studies.  Association studies identify SNPs 
that are associated with the trait in a given population, often because of linkage 
disequilibrium, whereas linkage studies identify loci that co-segregate with a trait 
within a family.  Linkage studies are often thought to be less powerful as the 
candidate region is often of a magnitude that includes many genes, more than one of 
which may be responsible for the observed linkage of that region to the disease, 
making it difficult or impossible to identify the causative genes.  Also, when using 
pedigrees, there is a strong bias towards SNPs that cause Mendelian forms of a 
complex disease which contribute little to the disease phenotype in a population. This 
was seen in the isolation of BRCA1 where pedigree based studies suggested a 
susceptibility to breast cancer at 85%.  When studies were performed on women with 
no prior history of breast cancer, the risk for carrying the mutation decreased to 36% 
[19].  This suggests that variants in BRCA1 account for a rare Mendelian early onset 
form of breast cancer and that the common late onset form has no strong genetic 
factors.  The success of any study depends on the number of individuals and SNPs 
genotyped as the power of linkage disequilibrium decreases with distance [20]. 
 
In this section several methods are listed for the use in population association studies 
or genome-wide linkage studies.   
 
BeadARRAY technology (Illumina) can be used for genome-wide studies [21] as well 
as detecting SNPs in candidate genes [22].  BeadARRAY uses a linkage mapping set 
of 1500 SNPs and 96 samples can be simultaneously analysed.  GeneChip is a 
microarray technique that can identify genomic regions associated with a phenotype 
[23].  The disadvantage of this method is it can’t be customized as a predefined set of 
SNPs is arrayed on the chip.  The main advantage is that up to a million SNPs can be 
targeted at the one time with results hopefully indicating a starting focus for future 
SNP identification.  For example, Affymetrix currently offers a chip that detects 
906,600 SNPs for genome-wide association studies.  MassEXTEND is a primer 
extension method that has the advantage over microarray techniques in that it can be 
customized for genome-wide scans and is therefore useful for targeted SNP 
identification.  This technique allows high-throughput genotyping and can analyse a 
specific set of SNPs (large or small numbers) in a large sample size [24].  TaqMan 
which is detailed in the above section can also be applied to large scale association 
studies [25].  This method is ideal for low to medium throughput assays rather than 
high-throughput.  Pyrosequencing has the advantage in that it provides the SNP 
genotype as well as sequence surrounding the SNP.  This technique uses sequencing 
by synthesis and detection by chemiluminescence.  Again this method suits low 
throughput assays [26].  Biotage offers pyrosequencing with simple and flexible assay 
design.  Invader assay has the advantage over most assays in that it doesn’t require a 
pre amplification step.  It combines enzymatic cleavage with fluorescence detection to 
produce a massive amplification of the diagnostic signal.  Multiplexing can be applied 
to this technique but only on a small scale so it isn’t suited for genotyping a large 
number of SNPs at the one time [27].   
 
Technologies for Novel SNP Identification for Drug Discovery 
The following techniques are for scanning DNA regions for unknown polymorphisms 
that are potentially associated with a phenotype or disease.  Usually there is biological 
evidence suggesting association of a gene with a disease and the genotyping methods 
are employed to characterise the gene for specific mutations.  In the case of the 
genome-wide approach, no one region of the genome has been identified previously 
for a potential association.  The choice of the genotyping method will impact 
significantly on the success of the association study. 
 
SNP Database Mining 
With the completion of the human genome project researchers have access to nearly 
12 million SNPs in different population groups for use in disease and drug response 
gene identification.  The Single Nucleotide Polymorphism database (dbSNP) is a 
public-domain archive for a collection of SNPs, small-scale multi-base deletions or 
insertions (also called deletion insertion polymorphisms or DIPs), and retroposable 
element insertions and microsatellite repeat variations (also called short tandem 
repeats or STRs) (http://www.ncbi.nlm.nih.gov/SNP).  Each dbSNP entry includes the 
sequence context of the polymorphism (i.e., the surrounding sequence), the 
occurrence frequency of the polymorphism (by population or individual), and the 
experimental method(s), protocols, and conditions used to assay the variation.  The 
dbSNP can be used for physical mapping, functional analysis, pharmacogenomics and 
association studies.  For example dbSNP notes possible functional implications of 
DNA sequence variations in terms of how the variation alters mRNA transcripts. 
 
DNA sequencing 
Direct DNA sequencing is still the gold standard for genotyping as it can be 
performed quickly, accurately and no other genotyping method is required for further 
SNP interrogation.  The platform of choice for automated DNA sequencing is now 
capillary electrophoresis with multiple capillaries using fluorescently labelled dye 
terminators.  Extension is initiated at a specific site on the template DNA by using 
oligonucleotides that are complementary to the template.  The oligonucleotide is 
extended using DNA polymerase and dNTPs as well as labelled ddNTPs.  
Incorporation of the ddNTPs results in fragments that are terminated only at positions 
where the particular nucleotide is used [28].  Each ddNTP fluoresces at a different 
wavelength allowing visualisation of the DNA sequence readout [29].  In comparison 
to other methods it is very sensitive and insertions and deletions can be identified 
along with SNPs.  However, it is still expensive when genotyping a large number of 
samples or analysing very large genes.  Other disadvantages include the need for an 
expensive automated sequence analyser and base-calling and analysis software.  High 
quality amplified DNA samples that are post-PCR purified are also required.  The 
latest development in sequencing has the potential to radically simplify and accelerate 
the sequencing process.  The next generation Roche Applied Science Genome 
Sequencer FLX system is based on pyrosequencing of hundreds of thousands of 
molecules immobilised on individual micro beads contained in micro reactors on a 
"picotiter plate" device.  The new technology provides the ability to sequence more 
than 400,000 reads per run (averaging 200 to 300 bases per read), equating to more 
than 100 Mb of sequence per run with a consensus-read accuracy of greater than 
99.99%. 
Solexa is a new sequencing technology by Illumina that can generate one billion bases 
of DNA sequence using a flow cell surface and fluorescently labelled modified 
nucleotides that have a reversible termination property.  This technology can produce 
high quality DNA sequence and is much cheaper compared to capillary-based 
methods.  Another next generation technology is SOLiD by Applied Biosystems 
which uses clonal cluster sequencing.  This technology reports capabilities of over 
three gigabases of mappable data per run.   
 
Denaturing High Performance Liquid Chromatography (DHPLC) 
This method is based on the concept that heteroduplex DNA (a hybrid formed 
between mismatched DNA strands) found in heterozygote samples has a different 
denaturing profile to homoduplexes (perfect DNA hybrids).  Many tests use properties 
of heteroduplexes to detect differences between two sequences.  The fragment of 
interest must first be identified and PCR products of up to around 800 bp are then 
generated.  An online MELT program (available at 
http://insertion.stanford.edu/melt.html) predicts melting temperature for PCR products 
under dHPLC conditions.  Heteroduplexes are formed when the PCR product is 
denatured by heat, allowed to cool and then eluted with a solvent gradient.  The PCR 
products are then analysed for abnormal elution profiles thereby discriminating 
heteroduplexes that have complex elution patterns, from homoduplexes, that normally 
elute as a uniform peak.  If elution profiles for heteroduplexes are the same shape, 
they are considered likely to be caused by the same polymorphism.  PCR products 
must be sequenced to identify the nature of the SNP.  Once the assay is optimised 
hundreds of samples can be automatically processed quickly, producing high 
sensitivity [30].  Drawbacks include the need for expensive equipment and the assay 
does not reveal the position or nature of the SNP.  Also samples that are homozygous 
for the phenotype are not revealed as they produce an identical profile to homozygous 
normal samples.  However, this can be overcome by mixing these samples with a 
heterozygous control DNA sample. 
 
SNP chips 
The DNA sequence containing the SNP is hybridised to the chip as a probe which is 
usually between 20-80 nucleotides and the labelled template hybridises to the chip if 
there is an exact match [31].  The base of the SNP is then identified by the location of 
the fluorescent signal.  SNP chips can be used for whole genome scans where all 
SNPs are genotyped and statistical association with a phenotype is analysed.  Once a 
statistical association has been identified, fine mapping on the region of interest can 
be performed using SNP chips on a larger sample set.  The advantage of this method 
is that it allows nearly a million SNPs to be analysed on the one chip.  The 
disadvantages are that complex and expensive instrumentation and technology is 
needed to amplify thousands of genes.  It may have limited uses in diagnostics as it 
tests one sample for thousands of potential phenotypes when usually only one 
phenotype is needed to be tested but in thousands of samples.  Some of the early 
applications of Affymetrix microarrays to detect SNPs have been cited for genes 
including HIV-1 [32], cystic fibrosis (CFTR) [33], and breast cancer in BRCA1 [34]. 
 Single Strand Confirmation Polymorphism (SSCP) analysis 
This method is based on single stranded DNA and its tendency to fold-up and form 
complex structures.  Single base differences alter possible secondary structures and 
thereby alter the conformation of the DNA.  Conformations and length differences 
can then be visualised by altered mobility when samples are run on a non-denaturing 
gel [35].  The process includes DNA amplification, denaturation, cooling and 
detection on a nondenaturing polyacrylamide gel.  Products are visualised on the gel 
by primer radiolabelling or silver-staining.  Control samples are run on the gel so 
differences in the wild-type pattern can be seen.  Conformational differences can also 
be enhanced by temperature, pH and buffer conditions [36].  Disadvantages are the 
position and nature of the change is not revealed and less than 200-400 bp of a gene 
can be analysed at the one time.  Therefore SSCP is usually followed up with 
sequencing to identify the location of the SNP and the base change.   Usually a second 
genotyping method such as ASO hybridisation is performed for high-throughput 
screening of the mutation.  The main advantages are low cost and relative simplicity 
of the assay.   
 
Denaturing Gradient Gel Electrophoresis (DGGE) 
DGGE is one of the few genotyping methods that detects both known and novel SNPs  
[37].  Again, this method relies on the formation of heteroduplexes.  Because of the 
mobility differences between heteroduplex and homoduplex DNA, electrophoretic 
mobility of the two molecules can be easily distinguished.  Primer design is pivotal to 
the success of the reaction and requires a 5´ poly(GC) extension (a GC clamp) primer.  
High specificity and sensitivity is achieved when primer design is optimal.  Like 
SSCP analysis, a disadvantage of the technique is that the position of the 
polymorphism is not revealed during the analysis so it must be followed up by DNA 
sequencing.    
 
Chemical Cleavage of Mismatch (CCM) 
This technique is based on the observation that mismatched bases in heteroduplexes 
are sensitive to cleavage by chemicals.  The test sample is first amplified, denatured 
and allowed to renature.  In heterozygous samples, heteroduplexes will form and 
Cytosines and thymines are oxidized by hydroxylamine and osmium tetroxide, 
respectively.  The sample is then incubated with piperidine which cleaves the DNA 
backbone at the site of the modified mismatched base.  Cleavage products are run on a 
fluorescence sequencer revealing the identity and location of the mutation.  
Advantages are that CCM has high sensitivity and large fragments in the range of 
several kilobases can be analysed [38].  The exact position of the polymorphism is 
also located by the size of the fragments generated.  Disadvantages include the use of 
toxic chemicals and the complexity of the methodology involved.  Toxicity can be 
overcome by substituting chemicals with enzymes that recognise and cleave 
mismatched bases. 
 
Conclusions 
There are a number of SNP genotyping methods available for use and choosing the 
right one depends on the specific application.  Firstly, it must be ascertained whether 
known SNPs are to be targeted or whether the study requires identification of novel 
SNPs.  A choice of methods then comes down to cost, robustness, automation, 
simplicity and accuracy.  Unfortunately no genotyping method will fit all these 
criteria so the decision depends on each assay requirement.  For SNP discovery work 
in pharmacogenomics, a high throughput system that detects thousands of 
polymorphisms at the one time is the most advantageous.  Then for routine SNP 
diagnostics, a simple and rapid assay is required that can ideally be performed in a 
doctor’s clinic.   
 
This review has critiqued only a small number of genotyping methods available.  New 
genotyping methods are being developed every day and their success will depend not 
only on the platform design but also on the speed of data analysis.  There are a 
number of assays that allow high throughput multiplex reactions but most of these 
assays require expensive instrumentation.  Some of the cheaper and simpler methods 
have the disadvantage of low specificity and don’t allow high throughput.  For routine 
diagnostics, the future lies in POC assays that allow rapid and cheap on-site testing in 
a doctor’s clinic.  The most challenging aspect for perfecting a genotyping assay is the 
final bioinformatics step for rapid data analysis.  This is particularly so for large-scale 
SNP genotyping projects.  With the growing information available from the Human 
Genome Project, bioinformatics is becoming the focus for genomic projects.  It is 
hoped that the future of SNP technologies will see a bridge between genetics and 
bioinformatics.    
 
Abbreviations 
SNPs Single Nucleotide Polymorphisms 
ADR Adverse Drug Reactions 
PCR Polymerase Chain Reaction 
RFLP Restriction Fragment Length Polymorphism 
ASO Allele Specific Oligonucleotide 
ASA Allele Specific Amplification 
ARMS Amplification Refractory Mutation System 
SNE Single Nucleotide Extension 
SPA Solid Phase Amplification 
MS Mass Spectrometry 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization Time of Flight  
POC Point of Care 
STR Short Tandem Repeats 
DHPLC Denaturing High Performance Liquid Chromatography 
SCCP Single Strand Confirmation Polymorphism 
DGGE Denaturing Gradient Gel Electrophoresis 
CCM Chemical Cleavage of Mismatch 
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